ArticleDiscover oncology2025
Apigenin combined with cisplatin suppressed the progression of colorectal cancer by targeting the KRT23/Wnt/β-catenin signaling pathway.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors.
Funding
Abstract
Colorectal cancer (CRC) represented a pervasive manifestation of malignant neoplasia within the digestive tract. Apigenin, exhibiting a multitude of physiological attributes and pharmacological actions, has undergone extensive scrutiny for its antitumor efficacy and benign toxicity profile. Cisplatin (DDP)-centered chemotherapy constituted a pivotal aspect of multidisciplinary therapeutic strategies. Nevertheless, resistance to DDP posed a considerable impediment to the efficacy of CRC chemotherapy. The aim of this investigation was to assess the impact of combining Apigenin with DDP on the proliferation and apoptotic processes of human CRC cells, while also delving into the underlying mechanisms. HCT116 and SW480 were cultivated and subjected to treatment with Apigenin (API) either as a monotherapy or in combination with cisplatin (DDP). Cell viability, proliferation, cycle distribution, apoptosis, migration, invasion and inflammatory factors were assessed. Western blot analysis was performed to detect the protein expression levels of Glut1, HK-2, KRT23, and β-catenin. In comparison to other treatment groups, the combined API and DDP group exhibited a more potent suppressive effect on cellular proliferation, migration, invasion, and glycolysis, while also enhancing apoptotic activity. Additionally, the combined API and DDP treatment group led to a reduction in the expression levels of KRT23, β-catenin, HK-2, and Glut1. Intriguingly, this combined treatment group demonstrated significantly elevated levels of TNF-α, IL-6, and IL-8 compared to the other groups. Notably, the overexpression of KRT23 was capable of reversing the changes induced by the combined API and DDP treatment. In vivo studies further validated that the combined API and DDP treatment suppressed tumor growth by inhibiting the expression of KRT23 and β-catenin. The present findings indicated that the combination of API with DDP has the potential to enhance colorectal cancer therapy through the modulation of the KRT23/Wnt/β-catenin signaling pathway. Our research may offer fresh perspectives and novel molecular therapeutic strategies for the treatment of colorectal cancer.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.